Ascendia

  MARKET NEWS

eschbach Introduces SAMI: The Next Evolution in AI-Empowered Process Manufacturing
Lonza Joins Centre for Continuous Manufacturing & Advanced Crystallisation to Enhance Service Offering
Cullinan Therapeutics Receives Approval From EMA to Initiate Phase 1 Trial of a Bispecific CD19 T Cell Engager Administered Subcutaneously in Patients With RA
AccuStem Sciences Signs Agreement to Access Blood Samples From Lung Cancer Screening Trial to Expedite MSC Commercialization Plan
Q32 Bio Doses First Patients in Both Part A Open-Label Extension & Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
Addgene Adds Science & Tech Leaders to its Management Team & Board of Directors
Conduit Pharmaceuticals Announces Leadership Changes
Researchers Recruit Killers to a Tumor Fight: Antibody Immunotherapies Developed to Treat Glioblastoma
Agno Pharma’s Particle Sciences, Inc. Achieves ISO 13485:2016 Certification

  EXPERT CONTENT & RESOURCES

How to Choose the Right CDMO for Your Pharmaceutical Project

How to Choose the Right CDMO for Your Pharmaceutical Project

This guide outlines the fundamental considerations to ensure your CDMO selection aligns with your project goals.

Understanding the Foundation of LNP Formulation Success

Understanding the Foundation of LNP Formulation Success

Download our eBook and discover everything you need to know about lipids for developing LNP therapies, including:….

Lyophilization Development: Quality by Design Approach

Lyophilization Development: Quality by Design Approach

Lyophilization, or freeze-drying, addresses stability challenges associated with complex APIs, biologics, microbiomes, gene therapies, viral vectors, liposomes, and nanoparticles……

Choosing the Right Particle for Your Nanomedicine Application

Choosing the Right Particle for Your Nanomedicine Application

Nanoparticles are revolutionizing the landscape of nanomedicine, enabling significant advancements in early detection, targeted drug delivery, disease monitoring, and imaging. Due to their nanoscale size, these particles….

  FEATURED EDITORIAL

  COMPANY PROFILE

Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists at the University of Kansas’ Higuchi Biosciences Center, for specific use in drug development and formulation. This unique technology has enabled 15 FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter International’s Nexterone, Acrotech Biopharma L.L.C.’s and CASI Pharmaceuticals’ Evomela, Melinta Therapeutics’ Baxdela, Pfizer’s VFEND IV and Sage Therapeutics’ Zulresso. The most recent approval in March 2023 was Novartis’ MEKINIST, a pediatric oral product. There are many Captisol-enabled products currently in various stages of development. Click here for more.

Click image to see Serán Bioscience’s latest video

latest video

 

  WHITEPAPERS & WEBINARS

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Efficient Development of Miniature Drug-Loaded Implants

WHITEPAPER - Efficient Development of Miniature Drug-Loaded Implants

Drug-eluting implants offer a unique approach to overcoming challenges associated with traditional drug delivery methods. They can provide sustained, continuous release of a therapeutic at the desired site of action.

Download our latest white paper, jointly authored with MeltPrep, to …

 WHITEPAPER - Formulating Custom Viscosity Blends With POLYOX™ Polyethylene Oxide 

 WHITEPAPER - Formulating Custom Viscosity Blends With POLYOX™ Polyethylene Oxide 


Excipient variability plays a critical role in pharmaceutical product design. A risk-based, scientific approach to Quality by Design (QbD) is essential to ensure consistent drug performance.

Our latest whitepaper delves into the impact of POLYOX™ PEO (Polyethylene Oxide) on drug …

WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations

WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations

The pharmaceutical industry has been acquainted with the promise of 3D printing for some time now, with many large pharma companies exploring the possibilities of the technology. However, 3D-printed pharmaceuticals have been largely relegated to niche markets and prototyping due …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 23 – Particle Design Technology
April 30 – Controlled Release